Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.18 is 400% above its 1-year average of 0.04, near the high end of its 1-year range (0.00–0.18).
As of the fiscal period ended Tuesday, June 30, 2026. 400.00% above its 12-month average of 0.04.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.18.
DEBT TO EQUITY RATIO
0.18
DEBT TO EQUITY RATIO AVG TTM
0.04
DEBT TO EQUITY RATIO AVG 3Y
0.00
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+400.00%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 686 covered companies
CURRENT VS SECTOR MEDIAN
+54.08%
vs the sector median at left
Mineralys Therapeutics, Inc.
Market Cap
$1.99B
Debt to Equity Ratio
0.18
TTM Avg
0.04
3Y Avg
0.00
5Y Avg
N/A
Market Cap
$1.98B
Debt to Equity Ratio
0.04
TTM Avg
0.04
3Y Avg
0.04
5Y Avg
0.07
Market Cap
$2.02B
Debt to Equity Ratio
0.10
TTM Avg
0.17
3Y Avg
0.15
5Y Avg
0.11
Market Cap
$2.04B
Debt to Equity Ratio
N/A
TTM Avg
2.21
3Y Avg
2.21
5Y Avg
2.21
Market Cap
$2.04B
Debt to Equity Ratio
2.13
TTM Avg
1.43
3Y Avg
0.96
5Y Avg
0.78
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | $1.99B | 0.18 | 0.04 | 0.00 | N/A |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.98B | 0.04 | 0.04 | 0.04 | 0.07 |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 0.10 | 0.17 | 0.15 | 0.11 |
| AxoGen, Inc. (AXGN)vs › | $1.96B | 0.08 | 0.59 | 0.64 | 0.60 |
| Progyny, Inc. (PGNY)vs › | $2.04B | 0.06 | 0.05 | 0.04 | 0.04 |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.04B | N/A | 2.21 | 2.21 | 2.21 |
| Fortrea Holdings Inc. (FTRE)vs › | $2.04B | 2.13 | 1.43 | 0.96 | 0.78 |
| Alvotech (ALVO)vs › | $2.06B | N/A | N/A | N/A | N/A |
| Immunome, Inc. (IMNM)vs › | $1.91B | 0.01 | 0.02 | 0.02 | 0.01 |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.07B | 0.01 | 0.01 | 0.01 | 0.01 |
Debt/Equity
0.18
Current Ratio
34.46
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.18 |
| 2026-03-31 | 0.00 |
| 2025-12-31 | 0.00 |
| 2025-09-30 | 0.00 |
| 2025-06-30 | 0.00 |
| 2025-03-31 | 0.00 |
| 2024-12-31 | 0.00 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.00 |
| 2023-12-31 | 0.00 |
| 2023-09-30 | 0.00 |
| 2023-06-30 | 0.00 |
| 2023-03-31 | 0.00 |
| 2022-12-31 | 0.00 |
| 2022-09-30 | 0.00 |
| 2022-06-30 | 0.00 |
| 2022-03-31 | 0.00 |
| 2021-12-31 | 0.00 |
